Brad Margus, CEO, Cerevance talks about discovering and developing novel therapies for central nervous system diseases using the Cerevance powerful NETSseq target discovery platform and their large collection of human brain tissue samples. Brad explains why the brain is such a challenging organ to study and their efforts to understand brain cell loss in such diseases as Parkinson's and Alzheimer's.
#brain #CNSdisorders #Parkinsons #Alzheimers #NETSseq
Cevevance.com
Download the transcript here
Empowered Patient Podcast